Both Janelidze et al. [127] and Barthelemy et al. [128] observed that while CSF p‐tau181 clearly distinguished AD from the non‐AD groups studied, CSF p‐tau217 more markedly distinguished between the groups, and it showed a stronger correlation with tau PET and amyloid PET in AD patients. This evidence concerns the gene MAPT and Alzheimer disease.